# PSMAfore (NCT04689828)

> 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04689828
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Novartis Pharmaceuticals
- Conditions: Prostatic Neoplasms
- Interventions: 177Lu-PSMA-617; 68Ga-PSMA-11; ARDT
- Enrollment: 469
- Primary outcome: Radiographic Progression Free Survival (rPFS)

## Commentary we found

- X threads: 118
- YouTube: 27
- Podcasts: 12

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=psmafore-nct04689828

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04689828", "email": "<work email>"}; the inbox owner confirms by the emailed link.